Zhiliang Cheng

Title: Zhiliang Cheng: Innovator in Tissue Calcification Treatment

Introduction

Zhiliang Cheng is a notable inventor based in New Haven, CT (US). He has made significant contributions to the field of medical treatments, particularly in addressing tissue calcification. With a total of 3 patents, his work has the potential to impact various health conditions associated with NPP1 deficiency.

Latest Patents

Zhiliang Cheng's latest patents focus on methods of treating tissue calcification. The inventions provide a method for treating NPP1 deficiency or NPP1-associated diseases, including idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The method involves administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels, which is crucial for managing these conditions.

Career Highlights

Zhiliang Cheng has worked with prominent companies in the pharmaceutical industry, including Alexion Pharmaceuticals, Inc. and Inozyme Pharma, Inc. His experience in these organizations has contributed to his expertise in developing innovative treatments for complex medical issues.

Collaborations

Zhiliang Cheng has collaborated with notable professionals in his field, including Anthony Quinn and Nelson Hsia. These partnerships have likely enhanced his research and development efforts, leading to impactful innovations.

Conclusion

Zhiliang Cheng's work in the treatment of tissue calcification showcases his dedication to advancing medical science. His patents and collaborations reflect a commitment to improving health outcomes for patients affected by various calcification-related diseases.